Healthcare tech firm CareCloud's Q3 revenue up 9%, beats expectations

Reuters11-06
Healthcare tech firm <a href="https://laohu8.com/S/CCLD">CareCloud</a>'s Q3 revenue up 9%, beats expectations

Overview

  • CareCloud Q3 revenue rises 9% yr/yr, beating analyst expectations

  • Company raises full-year 2025 revenue guidance to $117-$119 mln

  • CareCloud completes Medsphere acquisition, accelerates AI initiatives

Outlook

  • CareCloud raises full-year 2025 revenue guidance to $117-$119 mln

  • Company expects full-year 2025 adjusted EBITDA of $26-$28 mln

  • CareCloud projects full-year 2025 EPS of $0.10-$0.13

Result Drivers

  • ACQUISITIONS - Completion of Medsphere acquisition and others contributed to revenue growth and market expansion

  • AI INITIATIVES - AI integration into platforms enhanced performance and opened new sales opportunities

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$31.10 mln

$28.62 mln (3 Analysts)

Q3 EPS

$0.04

Q3 Adjusted Net Income

$4.40 mln

Q3 Adjusted EBITDA

$7.70 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the software peer group is "buy"

  • Wall Street's median 12-month price target for CareCloud Inc is $6.00, about 50.8% above its November 5 closing price of $2.95

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release: ID:nGNXbSFQC5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment